Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
results:exp434 [2025/10/22 21:28] – tyersadminresults:exp434 [2026/01/15 21:36] (current) – external edit 127.0.0.1
Line 10: Line 10:
 <accordion collapsed='true'> <accordion collapsed='true'>
 <panel title='Compound References' collapsed='true'> <panel title='Compound References' collapsed='true'>
-    ***<color #00a2e8>PubChem Name:</color>** %%Vemurafenib%% +    * **<color #00a2e8>PubChem Name:</color>** %%Vemurafenib%% 
-    ***<color #00a2e8>Synonyms:</color>** PLX4032; RG7204; RO5185426 +    * **<color #00a2e8>Synonyms:</color>** PLX4032; RG7204; RO5185426 
-    ***<color #00a2e8>CAS #:</color>** 918504-65-1 +    * **<color #00a2e8>CAS #:</color>** 918504-65-1 
-    ***<color #00a2e8>PubChem CID:</color>** [[https://pubchem.ncbi.nlm.nih.gov/compound/42611257|42611257]]+    * **<color #00a2e8>PubChem CID:</color>** [[https://pubchem.ncbi.nlm.nih.gov/compound/42611257|42611257]]
     * **<color #00a2e8>IUPAC:</color>** %%N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide%%     * **<color #00a2e8>IUPAC:</color>** %%N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide%%
-    ***<color #00a2e8>INCHI Name:</color>** InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28) +    * **<color #00a2e8>INCHI Name:</color>** InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28) 
-    ***<color #00a2e8>INCHI Key:</color>** GPXBXXGIAQBQNI-UHFFFAOYSA-N +    * **<color #00a2e8>INCHI Key:</color>** GPXBXXGIAQBQNI-UHFFFAOYSA-N 
-    ***<color #00a2e8>Molecular Weight:</color>** 489.9 +    * **<color #00a2e8>Molecular Weight:</color>** 489.9 
-    ***<color #00a2e8>Canonical SMILES:</color>** CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F +    * **<color #00a2e8>Canonical SMILES:</color>** CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F 
-    ***<color #00a2e8>Isomeric SMILES:</color>** NA +    * **<color #00a2e8>Isomeric SMILES:</color>** N/A 
-    ***<color #00a2e8>Molecular Formula:</color>** C23H18ClF2N3O3S+    * **<color #00a2e8>Molecular Formula:</color>** C23H18ClF2N3O3S
 {{:chemogenomics:structures:chem-0065.svg?nolink}} {{:chemogenomics:structures:chem-0065.svg?nolink}}
- 
 </panel> </panel>
  
Line 60: Line 59:
 </panel> </panel>
 </accordion> </accordion>
-==== Screen Results ====+==== Screen Summary ====
     * **<color #00a2e8>Round</color>**: 08     * **<color #00a2e8>Round</color>**: 08
     * **<color #00a2e8>Dose</color>**: 6.6µM     * **<color #00a2e8>Dose</color>**: 6.6µM
Line 68: Line 67:
  
  
-==== Screen Summary ====+==== Screen Results ====
  
  
 ^Sensitive/Resistant hits (FDR<0.05)^CRANKS^Score Plot^Top 30 Genes^Screen Similarity^Top 30 Sensitive GO terms^Top 30 Resistant GO terms^ ^Sensitive/Resistant hits (FDR<0.05)^CRANKS^Score Plot^Top 30 Genes^Screen Similarity^Top 30 Sensitive GO terms^Top 30 Resistant GO terms^
-|111/105|<color #e85500>[[https://files.tyerslab.com/files/public/chemogenomics/cranks/Vemurafenib_6.6uM_Round-8_exp434.txt|Scores]]</color>|<button type="primary" size="sm" modal="ScorePlot">View</button>|<button type="primary" size="sm" modal="modal_hits">View</button>|<button type="primary" size="sm" modal="modal_screen_similarity">View</button>|<button type="primary" size="sm" modal="modal_go_sensitive">View</button>|<button type="primary" size="sm" modal="modal_go_resistant">View</button>| +|111/105|<color #e85500>[[https://files.tyerslab.com/files/public/chemogenomics/cranks/Vemurafenib_6.6uM_Round-8_exp434.txt|Scores]]</color>|<button type="primary" size="sm" modal="ScorePlot">View</button>|<button type="primary" size="sm" modal="modal_hits">View</button>|<button type="primary" size="sm" modal="modal_screen_similarity">View</button>|<button type="default" size="sm" modal="modal_go_sensitive">View</button>|<button type="primary" size="sm" modal="modal_go_resistant">View</button>| 
-<modal id='ScorePlot' size='lg' title='Vemurafenib 6.6μM_R08_exp434'>+<modal id='ScorePlot' size='lg' title='Vemurafenib 6.6μM R08 exp434'>
 {{:chemogenomics:cranks_plots:exp434.png?nolink}} {{:chemogenomics:cranks_plots:exp434.png?nolink}}
 </modal> </modal>
Line 80: Line 79:
 <modal id="modal_hits" size="sm" title="Top 30 S/R Genes"> <modal id="modal_hits" size="sm" title="Top 30 S/R Genes">
 ^Gene^CRANKS Score^FDR^ ^Gene^CRANKS Score^FDR^
-|[[human_genes:G:GPR107|GPR107]]|-5.73|0.00| +|[[:human_genes:G:GPR107|GPR107]]|-5.73|0.00| 
-|[[human_genes:S:SLC39A9|SLC39A9]]|-5.44|0.00| +|[[:human_genes:S:SLC39A9|SLC39A9]]|-5.44|0.00| 
-|[[human_genes:A:APBA3|APBA3]]|-4.69|0.00| +|[[:human_genes:A:APBA3|APBA3]]|-4.69|0.00| 
-|[[human_genes:A:ACBD3|ACBD3]]|-4.58|0.00| +|[[:human_genes:A:ACBD3|ACBD3]]|-4.58|0.00| 
-|[[human_genes:A:ARL5B|ARL5B]]|-4.57|0.00| +|[[:human_genes:A:ARL5B|ARL5B]]|-4.57|0.00| 
-|[[human_genes:T:TBC1D23|TBC1D23]]|-4.55|0.00| +|[[:human_genes:T:TBC1D23|TBC1D23]]|-4.55|0.00| 
-|[[human_genes:T:TM9SF3|TM9SF3]]|-4.35|0.00| +|[[:human_genes:T:TM9SF3|TM9SF3]]|-4.35|0.00| 
-|[[human_genes:C:CHKA|CHKA]]|-4.33|0.00| +|[[:human_genes:C:CHKA|CHKA]]|-4.33|0.00| 
-|[[human_genes:A:ARL1|ARL1]]|-4.14|0.00| +|[[:human_genes:A:ARL1|ARL1]]|-4.14|0.00| 
-|[[human_genes:V:VKORC1L1|VKORC1L1]]|-4.13|0.00| +|[[:human_genes:V:VKORC1L1|VKORC1L1]]|-4.13|0.00| 
-|[[human_genes:L:LDLR|LDLR]]|-3.96|0.00| +|[[:human_genes:L:LDLR|LDLR]]|-3.96|0.00| 
-|[[human_genes:U:UGCG|UGCG]]|-3.65|0.00| +|[[:human_genes:U:UGCG|UGCG]]|-3.65|0.00| 
-|[[human_genes:S:SPTLC1|SPTLC1]]|-3.62|0.00| +|[[:human_genes:S:SPTLC1|SPTLC1]]|-3.62|0.00| 
-|[[human_genes:R:RALGAPB|RALGAPB]]|-3.54|0.00| +|[[:human_genes:R:RALGAPB|RALGAPB]]|-3.54|0.00| 
-|[[human_genes:M:MON2|MON2]]|-3.53|0.00| +|[[:human_genes:M:MON2|MON2]]|-3.53|0.00| 
-|[[human_genes:N:NRAS|NRAS]]|-3.41|0.00| +|[[:human_genes:N:NRAS|NRAS]]|-3.41|0.00| 
-|[[human_genes:C:C12orf23|C12orf23]]|-3.41|0.00| +|[[:human_genes:C:C12orf23|C12orf23]]|-3.41|0.00| 
-|[[human_genes:T:TBC1D22B|TBC1D22B]]|-3.37|0.00| +|[[:human_genes:T:TBC1D22B|TBC1D22B]]|-3.37|0.00| 
-|[[human_genes:M:METAP1|METAP1]]|-3.36|0.00| +|[[:human_genes:M:METAP1|METAP1]]|-3.36|0.00| 
-|[[human_genes:B:BRD1|BRD1]]|-3.33|0.00| +|[[:human_genes:B:BRD1|BRD1]]|-3.33|0.00| 
-|[[human_genes:K:KDSR|KDSR]]|-3.33|0.00| +|[[:human_genes:K:KDSR|KDSR]]|-3.33|0.00| 
-|[[human_genes:M:MMD|MMD]]|-3.31|0.00| +|[[:human_genes:M:MMD|MMD]]|-3.31|0.00| 
-|[[human_genes:M:MS4A13|MS4A13]]|-3.28|0.07| +|[[:human_genes:M:MS4A13|MS4A13]]|-3.28|0.07| 
-|[[human_genes:C:COPB2|COPB2]]|-3.25|<0.01| +|[[:human_genes:C:COPB2|COPB2]]|-3.25|<0.01| 
-|[[human_genes:H:HMGB2|HMGB2]]|-3.20|0.00| +|[[:human_genes:H:HMGB2|HMGB2]]|-3.20|0.00| 
-|[[human_genes:I:IGLL1|IGLL1]]|-3.17|0.00| +|[[:human_genes:I:IGLL1|IGLL1]]|-3.17|0.00| 
-|[[human_genes:Y:YIPF5|YIPF5]]|-3.17|0.00| +|[[:human_genes:Y:YIPF5|YIPF5]]|-3.17|0.00| 
-|[[human_genes:I:IER3IP1|IER3IP1]]|-3.16|0.00| +|[[:human_genes:I:IER3IP1|IER3IP1]]|-3.16|0.00| 
-|[[human_genes:S:SCAP|SCAP]]|-3.09|0.00| +|[[:human_genes:S:SCAP|SCAP]]|-3.09|0.00| 
-|[[human_genes:A:ARL5A|ARL5A]]|-3.08|0.00| +|[[:human_genes:A:ARL5A|ARL5A]]|-3.08|0.00| 
-|[[human_genes:B:BRAP|BRAP]]|2.94|<0.01| +|[[:human_genes:B:BRAP|BRAP]]|2.94|<0.01| 
-|[[human_genes:A:ATP8B2|ATP8B2]]|2.94|<0.01| +|[[:human_genes:A:ATP8B2|ATP8B2]]|2.94|<0.01| 
-|[[human_genes:H:HEATR5B|HEATR5B]]|3.05|0.00| +|[[:human_genes:H:HEATR5B|HEATR5B]]|3.05|0.00| 
-|[[human_genes:T:TNPO1|TNPO1]]|3.05|<0.01| +|[[:human_genes:T:TNPO1|TNPO1]]|3.05|<0.01| 
-|[[human_genes:D:DAZAP1|DAZAP1]]|3.07|0.00| +|[[:human_genes:D:DAZAP1|DAZAP1]]|3.07|0.00| 
-|[[human_genes:I:INSIG1|INSIG1]]|3.08|<0.01| +|[[:human_genes:I:INSIG1|INSIG1]]|3.08|<0.01| 
-|[[human_genes:W:WIBG|WIBG]]|3.13|<0.01| +|[[:human_genes:W:WIBG|WIBG]]|3.13|<0.01| 
-|[[human_genes:Z:ZBTB7A|ZBTB7A]]|3.14|0.00| +|[[:human_genes:Z:ZBTB7A|ZBTB7A]]|3.14|0.00| 
-|[[human_genes:T:TSC2|TSC2]]|3.16|0.00| +|[[:human_genes:T:TSC2|TSC2]]|3.16|0.00| 
-|[[human_genes:R:RQCD1|RQCD1]]|3.18|0.00| +|[[:human_genes:R:RQCD1|RQCD1]]|3.18|0.00| 
-|[[human_genes:S:SEC24C|SEC24C]]|3.25|0.00| +|[[:human_genes:S:SEC24C|SEC24C]]|3.25|0.00| 
-|[[human_genes:T:TVP23C-CDRT4|TVP23C-CDRT4]]|3.32|<0.01| +|[[:human_genes:T:TVP23C-CDRT4|TVP23C-CDRT4]]|3.32|<0.01| 
-|[[human_genes:M:MBOAT7|MBOAT7]]|3.34|0.00| +|[[:human_genes:M:MBOAT7|MBOAT7]]|3.34|0.00| 
-|[[human_genes:N:NUDT5|NUDT5]]|3.36|0.00| +|[[:human_genes:N:NUDT5|NUDT5]]|3.36|0.00| 
-|[[human_genes:Y:YIPF6|YIPF6]]|3.48|0.00| +|[[:human_genes:Y:YIPF6|YIPF6]]|3.48|0.00| 
-|[[human_genes:A:ABCG1|ABCG1]]|3.51|0.00| +|[[:human_genes:A:ABCG1|ABCG1]]|3.51|0.00| 
-|[[human_genes:R:RBM38|RBM38]]|3.67|0.00| +|[[:human_genes:R:RBM38|RBM38]]|3.67|0.00| 
-|[[human_genes:C:CHP1|CHP1]]|3.80|0.00| +|[[:human_genes:C:CHP1|CHP1]]|3.80|0.00| 
-|[[human_genes:F:FKBPL|FKBPL]]|3.80|0.00| +|[[:human_genes:F:FKBPL|FKBPL]]|3.80|0.00| 
-|[[human_genes:C:CARM1|CARM1]]|4.20|0.00| +|[[:human_genes:C:CARM1|CARM1]]|4.20|0.00| 
-|[[human_genes:S:SH3BP5L|SH3BP5L]]|4.23|0.00| +|[[:human_genes:S:SH3BP5L|SH3BP5L]]|4.23|0.00| 
-|[[human_genes:M:MBD2|MBD2]]|4.39|0.00| +|[[:human_genes:M:MBD2|MBD2]]|4.39|0.00| 
-|[[human_genes:T:TMEM30A|TMEM30A]]|4.45|0.00| +|[[:human_genes:T:TMEM30A|TMEM30A]]|4.45|0.00| 
-|[[human_genes:E:ELF1|ELF1]]|4.46|0.00| +|[[:human_genes:E:ELF1|ELF1]]|4.46|0.00| 
-|[[human_genes:K:KIAA2013|KIAA2013]]|4.53|0.00| +|[[:human_genes:K:KIAA2013|KIAA2013]]|4.53|0.00| 
-|[[human_genes:T:TRAPPC9|TRAPPC9]]|4.95|0.00| +|[[:human_genes:T:TRAPPC9|TRAPPC9]]|4.95|0.00| 
-|[[human_genes:T:TM9SF2|TM9SF2]]|5.18|0.00| +|[[:human_genes:T:TM9SF2|TM9SF2]]|5.18|0.00| 
-|[[human_genes:T:TRAPPC10|TRAPPC10]]|5.57|0.00| +|[[:human_genes:T:TRAPPC10|TRAPPC10]]|5.57|0.00| 
-|[[human_genes:R:RAB11A|RAB11A]]|6.49|0.00| +|[[:human_genes:R:RAB11A|RAB11A]]|6.49|0.00| 
-|[[human_genes:P:PITPNB|PITPNB]]|8.00|0.00|+|[[:human_genes:P:PITPNB|PITPNB]]|8.00|0.00|
 </modal> </modal>
  
Line 225: Line 224:
  
  
-<modal id="modal_go_sensitive" size="lg" title="Top 30 sensitive GO terms"> +<modal id="modal_go_sensitive" size="lg" title="Top 30 sensitive GO terms">No GO term hits below threshold. (FDR <0.05)</modal>
-^GO Term^Fold Change^Genes^ +
-|regulation of fat cell apoptotic process|613.67|SPTLC1| +
-|non-sequence-specific DNA binding, bending|613.67|HMGB2| +
-|clathrin heavy chain binding|136.37|GPR107,LDLR| +
-|intestinal lipid absorption|94.41|LDLR,UGCG| +
-|sphingoid metabolic process|61.37|SPTLC1,KDSR| +
-|positive regulation of erythrocyte differentiation|42.32|BRD1,HMGB2| +
-|protein localization to Golgi apparatus|42.32|ARL5B,ARL1| +
-|intestinal absorption|39.59|LDLR,UGCG| +
-|regulation of cholesterol metabolic process|36.10|LDLR,SCAP| +
-|COPII-coated ER to Golgi transport vesicle|20.69|YIPF5,IER3IP1,SCAP| +
-|endoplasmic reticulum to Golgi vesicle-mediated transport|19.64|COPB2,YIPF5,IER3IP1,SCAP| +
-|sphingolipid biosynthetic process|18.23|UGCG,SPTLC1,KDSR| +
-|regulation of endothelial cell proliferation|13.74|SLC39A9,NRAS,HMGB2| +
-|membrane lipid biosynthetic process|13.15|UGCG,SPTLC1,KDSR| +
-|trans-Golgi network|12.27|SLC39A9,ARL5B,TBC1D23,ARL1,YIPF5| +
-|coated vesicle|12.19|GPR107,LDLR,COPB2,YIPF5,IER3IP1,SCAP| +
-|Golgi vesicle transport|11.16|MON2,COPB2,YIPF5,IER3IP1,SCAP| +
-|Golgi apparatus subcompartment|8.43|SLC39A9,ARL5B,TBC1D23,ARL1,YIPF5| +
-|Golgi membrane|5.61|ACBD3,ARL1,UGCG,NRAS,COPB2,SCAP| +
-</modal>+
 <modal id="modal_go_resistant" size="lg" title="Top 30 resistant GO terms"> <modal id="modal_go_resistant" size="lg" title="Top 30 resistant GO terms">
 ^GO Term^Fold Change^Genes^ ^GO Term^Fold Change^Genes^
-|phosphatidylcholine floppase activity|157.80|ABCG1,ATP8B2| 
-|TRAPPII protein complex|122.73|TRAPPC10,TRAPPC9| 
-|phosphatidylcholine transporter activity|97.46|PITPNB,ABCG1,ATP8B2| 
-|TRAPP complex|78.90|TRAPPC10,TRAPPC9| 
-|flippase activity|73.64|TMEM30A,ATP8B2| 
-|floppase activity|73.64|ABCG1,ATP8B2| 
-|ATPase-coupled intramembrane lipid transporter activity|63.73|TMEM30A,ABCG1,ATP8B2| 
-|intramembrane lipid transporter activity|40.41|TMEM30A,ABCG1,ATP8B2| 
 |phospholipid transporter activity|36.22|PITPNB,TMEM30A,ABCG1,ATP8B2| |phospholipid transporter activity|36.22|PITPNB,TMEM30A,ABCG1,ATP8B2|
-|lipid translocation|30.68|TMEM30A,ABCG1,ATP8B2| 
-|regulation of membrane lipid distribution|27.16|TMEM30A,ABCG1,ATP8B2| 
-|regulation of intracellular steroid hormone receptor signaling pathway|24.01|CARM1,CNOT9,ZBTB7A| 
-|phospholipid transport|23.01|PITPNB,TMEM30A,ABCG1,ATP8B2| 
-|vesicle budding from membrane|22.39|TRAPPC10,TRAPPC9,SEC24C| 
-|endoplasmic reticulum to Golgi vesicle-mediated transport|17.67|TRAPPC10,TRAPPC9,YIPF6,SEC24C| 
-|organophosphate ester transport|15.13|PITPNB,TMEM30A,ABCG1,ATP8B2| 
-|lipid transporter activity|13.15|PITPNB,TMEM30A,ABCG1,ATP8B2| 
-|Golgi vesicle transport|10.04|PITPNB,TRAPPC10,TRAPPC9,YIPF6,SEC24C| 
-|membrane organization|6.07|PITPNB,TRAPPC10,TRAPPC9,TMEM30A,CHP1,ABCG1,SEC24C,ATP8B2| 
 </modal> </modal>
  
  • Last modified: 2025/10/22 21:28
  • by tyersadmin